Clinical Trials Directory

Trials / Unknown

UnknownNCT03393442

Evaluation of Gadolinium Deposits in Healthy Women Participating in a High Risk Screening Program for Early Breast Cancer Detection

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Medical University of Vienna · Academic / Other
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Purpose: To determine whether patients at high risk to develop breast cancer having received at least 6 cumulative dosages of macrocyclic Gd-based contrast media in the context of breast cancer screening by means of contrast-enhanced MRI. Methods: Diagnostic study encompassing two arms: first, 50 patients having received ≥6 dosages of macrocyclic Gd-based contrast media in the course of MRI-based breast cancer screening will undergo brain MRI assessment for signal alterations due to Gd-deposits. The second arm consists of 50 healthy volunteers that never received Gd-based contrast agents, and undergoes the same brain MRI assessment as the patient-based arm 1 of the study. Signal intensities will be compared to assess the potential presence or absence of macrocyclic Gd-based contrast agent deposits in the brain. In case of presence of signal alterations in arm 1 these will be further stratified by number of previously administered macrocyclic Gd-contrast agent doses. Projected outcome: High cumulative dosages of macrocyclic Gd-based contrast agent either result or do not result in brain MRI signal alterations in healthy women participating in a high-risk screening program for the early detection of breast cancer that necessitates Gd-contrast agent enhanced breast MRI at regular intervals.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBrain MRI scanDiagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.

Timeline

Start date
2017-11-25
Primary completion
2018-03-15
Completion
2018-04-01
First posted
2018-01-08
Last updated
2018-01-09

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT03393442. Inclusion in this directory is not an endorsement.